Immunosupressant Drugs Flashcards Preview

Pharmacology > Immunosupressant Drugs > Flashcards

Flashcards in Immunosupressant Drugs Deck (42):
1

mechanism of cyclosporine

binds cyclophilin and inhibits T cell activation by inhibiting calcineurin and preventing IL-2 transcription

2

SEs of cyclosporine

nephrotoxicity, HTN, HLD, neurotoxicity, gingival hyperplasia, hirsutism

3

mechanism of tacrolimus

binds FK506 and inhibits T cell activation by inhibiting calcineurin and preventing IL-2 transcription

4

SEs of tacrolimus

nephrotoxicity, neurotoxicity

5

mechanism of sirolimus/rapamycin

binds FKBP and inhibits B and T cell activation by inhibiting mTOR and preventing IL-2 transcription

6

mechanism of azathioprine

precursor of 6-mercaptopurine --> inhibits lymphocyte proliferation by blocking nucleotide synthesis

7

never give azathioprine/6-MP with ______ because _____

- allopurinol
- toxicity increases when XO inhibitied (XO breaks down the drug)

8

SEs of azathioprine

BM suppression

9

glucocorticoids

inhibition of NF-kB --> suppression of B and T cell function by suppressing transcription of many cytokines

10

-sone vs -solone

-sone: prodrug absorbed better in GI tract
-solone: active form (topical, inhaled)

11

cromolyn

inhibition of mast cell degranulation

12

adalimumab

MAB vs TNFa

13

etanercept

soluble TNFa receptor

14

H1 antagonists that enter CNS:

- diphenhydramine
- promethazine

15

H1 antagonists that do NOT enter CNS:

- fexofenadine
- loratidine

16

filagrastim

G-CSF to recover BM (granulocytes)

17

sargramostim

GM-CSF to recover BM (granulocytes, monocytes)

18

IFNa used for:

HepB, HepC, Kaposi sarcoma, malignant melanoma, hairy cell leukemia, condyloma acuminata, RCC

19

IFNb used for:

MS

20

IFNy used for:

CGD

21

bevacizumab, ranibizumab

VEGF MAB

22

cetuximab, erlotinib, gefitinib

EGFR MAB

23

rituximab

CD20 MAB

24

trastuzumab

Her2 MAB

25

abciximab

platelet GP IIb/IIIa MAB used in pts undergoing percutaneous coronary intervention

26

denosumab

RANKL MAB (mimics osteoprotegrin)

27

omalizumab

IgE MAB

28

palivizumab

RSV F protein MAB - prophylaxis for high risk infants

29

SEs of sirolimus

insulin resistance, HLD

30

Sirolimus does not cause _____ so it is drug of choice for ____ transplants.

nephrotoxicity, kidney

31

basiliximab

IL-2 receptor ab (prevents T cell activation)

32

mechanism of mycophenolate mofetil

reversibly inhibits IMP dehydrogenase to prevent purine synthesis in lymphocytes (used in SLE)

33

SEs of CSTs include:

- Cushing syndrome:osteoporosis, muscle atrophy, hyperglycemia, adrenocortical atrophy
- peptic ulcers
- psychosis
- avascular necrosis of the femoral head

34

WBCs go ____ with CSTs because the cells ____.

up, demargination from vessel walls

35

aldesleukin

IL-2 agent used for RCC, melanoma

36

romiplostim

TPO analogue

37

eltrombopag

TPO receptor agonist

38

oprelvekin

IL-11 analogue used for thrombocytopenia

39

alemtuzumab

CD52 mab, CLL

40

adalimumab, infliximab

TNFa MAB

41

etanercept

TNFa soluble decoy receptor

42

eculizumab

C5 ab, used in PNH to prevent complement destruction of RBCs